Syntheses, structures, and mesomorphism of a series of Cu(II) salen complexes with 4-substituted long alkoxy chains

This is a preprint of an article whose final and definitive form has been published in the MOLECULAR CRYSTALS AND LIQUID CRYSTALS © 2007 copyright Taylor & Francis; MOLECULAR CRYSTALS AND LIQUID CRYSTALS is available online at : http://www.informaworld.com/openurl?genre=article&issn=1542-1406&volume=466&issue=1&spage=129ArticleMOLECULAR CRYSTALS AND LIQUID CRYSTALS. 466(1): 129-147 (2007)journal articl

Dual-mode humidity detection using a lanthanide-based metal-organic framework: towards multifunctional humidity sensors

Combined photoluminescence and impedance spectroscopy studies show that a europium-based metal–organic framework behaves as a highly effective and reliable humidity sensor, enabling dual-mode humidity detection

High proton conductivity in cyanide-bridged metal-organic frameworks: understanding the role of water

We investigate and discuss the proton conductivity properties of the cyanide-bridged metal–organic framework (MOF) [Nd(mpca)2Nd(H2O)6Mo(CN)8]·nH2O (where mpca is 5-methyl-2-pyrazinecarboxylate). This MOF is one of an exciting class of cyanide-bridged materials that can combine porosity with magnetism, luminescence, and proton conductivity. Specifically, we show that this material features highly hydrophilic open channels filled with water molecules. They enable a high proton conductivity, as much as 10−3 S cm−1. A rich hydrogen-bonding network, formed by the ligands' carboxylate groups with both coordinated and lattice water molecules, facilitates this high proton conductivity. Combined thermogravimetric studies, FTIR spectroscopy and PXRD analysis show that upon heating at 80 °C, the lattice water molecules are removed without any change in the framework. Further heating at 130 °C results in a partial removal of the coordinated water molecules, while still retaining the original framework. These activated MOFs shows an increasing conductivity from ∼10−9 S cm−1 to ∼10−3 S cm−1 when the relative humidity increases from 0% to 98%. Our studies show that the increase in proton conductivity is correlated with the re-hydration of the framework with lattice water molecules. The Arrhenius activation energy for the proton conductivity process is low (Ea = 37 kJ mol−1), indicating that the protons “hop” through the channels following the Grotthuss mechanism. The fact that this MOF is remarkably stable both under high humidity conditions and at relatively high temperatures (up to 130 °C) makes it a good candidate for real-life applications

Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma

The aim of this study was to assess the clinical characteristics and outcome of patients with either primary peritoneal carcinoma (PPC) or ovarian serous carcinoma (OSC) treated with paclitaxel plus carboplatin chemotherapy. We retrospectively identified 22 PPC patients and 55 stage III–IV OSC patients treated between 2002 and 2007. After exploratory laparotomy, all patients received paclitaxel and carboplatin every 3 weeks, with the goal of optimal cytoreduction. There were no statistically significant differences between the PPC and OSC groups with regard to tumor stage, residual tumor after debulking surgery (initial or interval), serum cancer antigen (CA) 125 levels at diagnosis, and completion of first-line chemotherapy. The progression-free survival (PFS) durations were 12.7 months (95% CI, 6.3–18.5) in the patients with PPC and 15.9 months (95% CI, 13.3–18.5) in those with OSC (p = 0.016). However, the median survival durations were 26.5 months (95% CI, 14.6–38.3) in the patients with PPC and 38 months (95% CI, 23.8–53.8) in those with OSC (p = 0.188). Survival was longer for all patients whose CA125 levels normalized to 26 U/ml during and after treatment. Overall survival (OS) of the patients with PPC was similar to that of the patients with OSC, suggesting that management for advanced-stage OSC would be similar to that for PPC. The combination of optimal debulking with paclitaxel plus carboplatin chemotherapy may offer patients the most effective treatment. The CA125 nadir after cytoreductive surgery can be considered a prognostic factor for OS and PFS in patients with PPC

Терапевтические возможности лечения артериальной гипертензии у детей

Arterial hypertension is a major health problem in developed and developing countries, affecting approximately one billion people in the world and its evolution is affects primarily younger people, by that representing a major public health problem due to its major complications. In the treatment of arterial hypertension in children, it is very important the non-medical treatment, knowing the fact that among other risk factors, obesity plays a huge role and also life style changes, which are the first choice for treatment. The possibilities to treat arterial hypertension in children are limited, despite the large numbers of drugs for the adult population and continuous progress in this direction. This article is a summary of literature sources, referring to non-medical and pharmacological treatment, evaluate the most important classes of drugs accepted and used in the treatment of arterial hypertension in children, allowing us to focus on the recently introduced drugs to treat arterial hypertension in children and teenagers.Артериальная гипертензия является одной из основных проблем здравоохранения как в развитых, так и в развивающихся странах. Поражает, примерно, один миллиард людей во всём мире, имеет на сегодняшний день тенденцию к уменьшению возрастной категории и представляет собой серьезную проблему общественного здравоохранения в связи с её серьезными осложнениями и возрастающей заболеваемостью. Исходя из того, что ессенциальная артериальная гипертензия является результатом ожирения, а также множества факторов риска, в лечении артериальной гипертензии у детей особое значение уделяется немедикаментозным методам, которые преследуют изменение стиля жизни, как метод первого выбора. Несмотря на то, что существует огромное множество антигипертензивных препаратов и существенный прогресс в контроле артериальной гипертензии у взрослого населения, возможности назначения лечения для детей ограничены. Данная статья представляет собой литературный обзор немедикаментозного и медикаментозного лечения артериальной гипертензии, что позволяет оценить наиболее важные классы современных медицинских препаратов, разрешённых для лечения артериальной гипертензии у детей и подростков

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/ Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma

Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/ LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler® have been approved for the maintenance treatment of patients with asthma inadequately controlled with medium-or high-dose ICS or medium-or high-dose ICS/LABA treatment. Objective: Once-daily (o.d.) formulations of MF/IND/GLY and MF/IND at different MF dose strengths have been compared with twice-daily (b.i.d.) fluticasone propionate/salmeterol xinafoate (FLU/SAL), and b.i.d. FLU/SAL+ o.d. tiotropium (TIO) in the PALLADIUM, IRIDIUM and ARGON studies. Methods: The similarity in study design and consistent outcomes in these studies prompted the pooling of data in this review to better characterise these novel once-daily controller formulations. Results: Pooled data from PALLADIUM and IRIDIUM studies showed comparable or greater efficacy with o.d. MF/IND formulations versus b.i.d. FLU/SAL. The o.d. MF/IND/GLY was superior to b.i.d. FLU/SAL in the IRIDIUM study, and similar to, if not more efficacious than b.i.d. FLU/SAL + o.d. TIO in the ARGON study. Conclusion: These formulations therefore provide novel once-daily treatment options for patients across asthma severity and flexibility for clinicians to step-up or step-down the treatment using the same device and formulations.</p

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/ Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma

Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/ LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler® have been approved for the maintenance treatment of patients with asthma inadequately controlled with medium-or high-dose ICS or medium-or high-dose ICS/LABA treatment. Objective: Once-daily (o.d.) formulations of MF/IND/GLY and MF/IND at different MF dose strengths have been compared with twice-daily (b.i.d.) fluticasone propionate/salmeterol xinafoate (FLU/SAL), and b.i.d. FLU/SAL+ o.d. tiotropium (TIO) in the PALLADIUM, IRIDIUM and ARGON studies. Methods: The similarity in study design and consistent outcomes in these studies prompted the pooling of data in this review to better characterise these novel once-daily controller formulations. Results: Pooled data from PALLADIUM and IRIDIUM studies showed comparable or greater efficacy with o.d. MF/IND formulations versus b.i.d. FLU/SAL. The o.d. MF/IND/GLY was superior to b.i.d. FLU/SAL in the IRIDIUM study, and similar to, if not more efficacious than b.i.d. FLU/SAL + o.d. TIO in the ARGON study. Conclusion: These formulations therefore provide novel once-daily treatment options for patients across asthma severity and flexibility for clinicians to step-up or step-down the treatment using the same device and formulations.</p

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/ Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma

Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/ LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler® have been approved for the maintenance treatment of patients with asthma inadequately controlled with medium-or high-dose ICS or medium-or high-dose ICS/LABA treatment. Objective: Once-daily (o.d.) formulations of MF/IND/GLY and MF/IND at different MF dose strengths have been compared with twice-daily (b.i.d.) fluticasone propionate/salmeterol xinafoate (FLU/SAL), and b.i.d. FLU/SAL+ o.d. tiotropium (TIO) in the PALLADIUM, IRIDIUM and ARGON studies. Methods: The similarity in study design and consistent outcomes in these studies prompted the pooling of data in this review to better characterise these novel once-daily controller formulations. Results: Pooled data from PALLADIUM and IRIDIUM studies showed comparable or greater efficacy with o.d. MF/IND formulations versus b.i.d. FLU/SAL. The o.d. MF/IND/GLY was superior to b.i.d. FLU/SAL in the IRIDIUM study, and similar to, if not more efficacious than b.i.d. FLU/SAL + o.d. TIO in the ARGON study. Conclusion: These formulations therefore provide novel once-daily treatment options for patients across asthma severity and flexibility for clinicians to step-up or step-down the treatment using the same device and formulations.</p

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/ Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma

Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/ LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler® have been approved for the maintenance treatment of patients with asthma inadequately controlled with medium-or high-dose ICS or medium-or high-dose ICS/LABA treatment. Objective: Once-daily (o.d.) formulations of MF/IND/GLY and MF/IND at different MF dose strengths have been compared with twice-daily (b.i.d.) fluticasone propionate/salmeterol xinafoate (FLU/SAL), and b.i.d. FLU/SAL+ o.d. tiotropium (TIO) in the PALLADIUM, IRIDIUM and ARGON studies. Methods: The similarity in study design and consistent outcomes in these studies prompted the pooling of data in this review to better characterise these novel once-daily controller formulations. Results: Pooled data from PALLADIUM and IRIDIUM studies showed comparable or greater efficacy with o.d. MF/IND formulations versus b.i.d. FLU/SAL. The o.d. MF/IND/GLY was superior to b.i.d. FLU/SAL in the IRIDIUM study, and similar to, if not more efficacious than b.i.d. FLU/SAL + o.d. TIO in the ARGON study. Conclusion: These formulations therefore provide novel once-daily treatment options for patients across asthma severity and flexibility for clinicians to step-up or step-down the treatment using the same device and formulations.</p